Cooper Co AI Stock Analysis
Want to see COO full AI Analyst Report?
Cooper Co (COO) AI Stock Analysis
Cooper Co
(NASDAQ:COO)
COO’s score is held back primarily by sharply weaker TTM cash flow and compressed operating margins, despite solid revenue growth and a conservatively levered balance sheet. Technically, the stock is in a strong downtrend (well below key moving averages) even though it is extremely oversold. Valuation is moderate at ~18.5x earnings, while the latest earnings call was supportive on execution/cash flow and capital returns but tempered by soft near-term guidance and expected Q4 margin pressure.
Cooper Co Key Performance Indicators (KPIs)
Revenue by SegmentShows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
CooperVision is the steady-growth engine—consistent organic lens demand and new product momentum (MiSight, daily silicone hydrogel) underpin resilience even as Asia softness and near-term margin pressure from FX, tariffs and inventory optimization bite. CooperSurgical is the faster-growth lever—fertility, genomics and capital equipment have materially lifted contribution since 2022, and management’s strategic review (broad external interest) could unlock value or introduce execution risk. Monitor how litigation payouts and any transaction proceeds affect buybacks, FCF allocation and near-term margin recovery.
Cooper Co (COO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $11.55B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.51M
- Price to Earnings (P/E)
- 20.8
- Beta (1Y)
- 0.55
- Revenue Growth
- 4.73%
- EPS Growth
- 43.89%
- Country
- US
- Employees
- 15,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Cooper Co Business Overview & Revenue Model
Company Description
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact...
Cooper Co Earnings Call Summary
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For Q4, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%; CooperVision revenue of $692 million to $706 million, down 2% to flat organically; CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%; interest expense of roughly $25 million; a non-GAAP effective tax rate of roughly 16%; non-GAAP EPS of $1.05 to $1.09; and around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million. MiSight growth is expected to be in the low teens in Q4, resulting in roughly 20% growth for this full year, while the company expects $2.2 billion of cumulative free cash flow in fiscal '26 to 2028 and, in fiscal 2027, its scheduled GILTI increase of roughly 2% to increase the non-GAAP effective tax rate from roughly 15.5% this year to roughly 17.5% in fiscal 2027.
Cooper Co Financial Statement Overview
Summary
Revenue growth is solid (~13.9% TTM) and the balance sheet is conservative (debt-to-equity ~0.31), but operating profitability compressed sharply (EBIT margin ~7.2% TTM vs ~15.4% prior annual) and cash generation deteriorated materially (operating cash flow ~$182M TTM vs ~$796M in FY2025; free cash flow down ~84%). Weak TTM cash conversion versus net income raises the biggest near-term quality risk.
Income Statement
74PositiveBalance Sheet
78PositiveCash Flow
38Negative| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.24B | 4.09B | 3.90B | 3.59B | 3.31B | 2.92B |
| Gross Profit | 2.70B | 2.48B | 2.60B | 2.36B | 2.14B | 1.96B |
| EBITDA | 910.30M | 1.05B | 1.07B | 885.90M | 878.70M | 823.90M |
| Net Income | 570.30M | 374.90M | 392.30M | 294.20M | 385.80M | 2.94B |
Balance Sheet | ||||||
| Total Assets | 12.67B | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 154.70M | 110.60M | 107.60M | 120.90M | 138.20M | 95.90M |
| Total Debt | 2.54B | 2.78B | 2.58B | 2.57B | 2.76B | 1.48B |
| Total Liabilities | 4.34B | 4.16B | 4.23B | 4.11B | 4.32B | 2.66B |
| Stockholders Equity | 8.33B | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B |
Cash Flow | ||||||
| Free Cash Flow | 678.00M | 433.70M | 288.10M | 215.00M | 450.40M | 524.20M |
| Operating Cash Flow | 1.03B | 796.10M | 709.30M | 607.50M | 692.40M | 738.60M |
| Investing Cash Flow | -361.50M | -372.90M | -764.60M | -449.00M | -1.83B | -450.30M |
| Financing Cash Flow | -641.00M | -425.90M | 39.20M | -173.90M | 1.19B | -311.40M |
Cooper Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Negative. The current price of 60.72 is below the 20-day moving average (MA) of 61.62, above the 50-day MA of 58.19, and below the 200-day MA of 67.77, indicating a neutral trend. The MACD of 0.85 indicates Positive momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 18.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COO.
Cooper Co Risk Analysis
Cooper Co disclosed 41 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksCooper Co Peers Comparison
Overall Rating
MMSI71Outperform
BLCO65Neutral
STAA59Neutral
BAX58Neutral
TFX57Neutral
COO54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $5.06B | 31.49 | 9.65% | ― | 9.34% | 33.77% | |
| 65Neutral | $7.45B | -67.36 | -1.73% | ― | 8.88% | 63.73% | |
| 59Neutral | $1.28B | 2542.43 | 0.15% | ― | 42.36% | ― | |
| 58Neutral | $13.33B | -18.63 | -11.62% | 0.16% | 5.33% | -164.67% | |
| 57Neutral | $6.33B | 19.24 | 9.74% | 0.85% | -29.30% | ― | |
| 54Neutral | $11.55B | 20.78 | 6.88% | ― | 4.73% | 43.89% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| COO | Cooper Companies | 60.72 | -11.43 | -15.84% | |
| BAX | Baxter International Inc | 25.76 | 8.11 | 45.91% | |
| MMSI | Merit Medical | 84.49 | 0.80 | 0.96% | |
| STAA | Staar Surgical Company | 25.56 | -0.89 | -3.36% | |
| TFX | Teleflex | 159.55 | 54.92 | 52.49% | |
| BLCO | Bausch + Lomb Corporation | 20.83 | 6.21 | 42.48% |
Cooper Co Corporate Events
Cooper Co Announces Leadership Reshuffle and Governance Changes
NeutralOn October 27, 2026, CooperCompanies announced a major leadership reshuffle, with long-time executive Albert G. White III resigning as president, CEO and board member, and independent director Walter M. Rosebrough Jr. taking over as interim executive...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026
